Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd Gerber

Showing results (131-140 of 173) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancerGunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)Jens Huober, Peter A Fasching, Claus Hanusch, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2023
Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological imagesFrederik Marmé, Eva Krieghoff-Henning, Bernd Gerber, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsGunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2019
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSeptoMichael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
Breast Cancer Research and Treatment|February 8, 2014
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinomaSibylle Loibl, Cristina Volz, Christine Mau, et al.
Cancers|February 15, 2022
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto TrialBernd Gerber, Andreas Schneeweiss, Volker Möbus, et al.
The New England Journal of Medicine|August 27, 2005
A pooled analysis of bone marrow micrometastasis in breast cancerStephan Braun, Florian D Vogl, Bjørn Naume, et al.
Pageof 18

Showing results (131-140 of 173) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancerGunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)Jens Huober, Peter A Fasching, Claus Hanusch, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2023
Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological imagesFrederik Marmé, Eva Krieghoff-Henning, Bernd Gerber, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsGunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2019
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSeptoMichael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
Breast Cancer Research and Treatment|February 8, 2014
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinomaSibylle Loibl, Cristina Volz, Christine Mau, et al.
Cancers|February 15, 2022
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto TrialBernd Gerber, Andreas Schneeweiss, Volker Möbus, et al.
The New England Journal of Medicine|August 27, 2005
A pooled analysis of bone marrow micrometastasis in breast cancerStephan Braun, Florian D Vogl, Bjørn Naume, et al.
Pageof 18